Skip to main content

Table 1 The demographic and clinical data

From: A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients

Parameters

Fingolimod-treatment group

IFNβ-treatment group

Age (mean ± SD)

39.08 ± 7.63

36.83 ± 7.24

Sex ratio (Female/male)

24/6

18/7

Disease duration

8.20 ± 3.42

8.77 ± 2.5

EDSS (mean ± SD)

4.92 ± 0.73

4.52 ± 1.09